Fennec Pharmaceuticals Inc. (FENC)

NASDAQ: FENC · IEX Real-Time Price · USD
8.10
+0.06 (0.75%)
Sep 30, 2022 4:00 PM EDT - Market closed
0.75%
Market Cap 212.53M
Revenue (ttm) n/a
Net Income (ttm) -17.38M
Shares Out 26.24M
EPS (ttm) -0.63
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 184,143
Open 7.96
Previous Close 8.04
Day's Range 7.75 - 8.19
52-Week Range 3.82 - 10.08
Beta 0.09
Analysts Buy
Price Target 10.81 (+33.5%)
Earnings Date Nov 8, 2022

About FENC

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina. [Read more...]

Industry Biotechnology
IPO Date Jun 5, 2001
CEO Rostislav Raykov
Employees 10
Stock Exchange NASDAQ
Ticker Symbol FENC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for FENC stock is "Buy." The 12-month stock price forecast is 10.81, which is an increase of 33.46% from the latest price.

Price Target
$10.81
(33.46% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Fennec Pharmaceuticals Announces Second Closing of $20 Million Investment from Petrichor

~ Under the Terms of the Previously Announced Investment Agreement, $5 Million Already Funded Upon Initial Closing, Which Occurred on August 19, 2022, and $20 Million to be Funded Upon FDA Approval of P...

5 days ago - GlobeNewsWire

Feneca (FENC) Gets FDA Nod for Cancer-Related Hearing Loss Drug

Feneca Pharmaceuticals (FENC) receives FDA approval for Pedmark to reduce the risk of ototoxicity associated with cisplatin in pediatric patients with localized, non-metastatic solid tumors.

1 week ago - Zacks Investment Research

Fennec Pharmaceuticals Announces FDA Approval of PEDMARK® (Sodium Thiosulfate Injection)

~ PEDMARK® is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic Solid Tumors ~

1 week ago - GlobeNewsWire

Fennec Pharmaceuticals Closes First $5 Million Investment From Petrichor

~ Under the Terms of the Investment Agreement, $5 Million to be Funded on initial closing and $20 Million to be Funded Upon Potential FDA Approval of PEDMARK TM ~

1 month ago - GlobeNewsWire

Fennec Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Business Update

~ PEDMARK TM FDA Prescription Drug User Fee Act (PDUFA) Target Action Date Set for September 23, 2022 ~

1 month ago - GlobeNewsWire

Fennec Pharmaceuticals Announces Up to $45 Million Investment From Petrichor

~ Under the Terms of the Investment Agreement, $5 Million to be Funded on initial closing and $20 Million to be Funded Upon Potential FDA Approval of PEDMARK TM ~

2 months ago - GlobeNewsWire

Has Adherex Technologies (FENC) Outpaced Other Medical Stocks This Year?

Here is how Adherex Technologies Inc. (FENC) and U.S. Physical Therapy (USPH) have performed compared to their sector so far this year.

3 months ago - Zacks Investment Research

Fennec Announces Results of Annual Meeting

RESEARCH TRIANGLE PARK, N.C., June 14, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circu...

3 months ago - GlobeNewsWire

Wall Street Analysts Predict an 80% Upside in Adherex Technologies Inc. (FENC): Here's What You Should Know

The mean of analysts' price targets for Adherex Technologies Inc. (FENC) points to an 80.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreeme...

3 months ago - Zacks Investment Research

Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., May 23, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique f...

4 months ago - GlobeNewsWire

Fennec Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business Update

~ FDA Prescription Drug User Fee Act (PDUFA) Target Action Date Set for September 23, 2022 ~

4 months ago - GlobeNewsWire

Can Adherex Technologies Inc. (FENC) Climb 92% to Reach the Level Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 91.9% in Adherex Technologies Inc. (FENC). While the effectiveness of this highly sought-after metric is question...

4 months ago - Zacks Investment Research

Fennec Pharmaceuticals Announces FDA Acceptance for Filing of New Drug Application Resubmission for PEDMARK™

~ Prescription Drug User Fee Act (PDUFA) target action date set for September 23, 2022 ~ ~ Prescription Drug User Fee Act (PDUFA) target action date set for September 23, 2022 ~

5 months ago - GlobeNewsWire

FENC Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Fennec Pharmaceuticals Inc. Investors of Class Action...

NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Fennec Pharmaceuticals Inc. ("Fennec" or the "Co...

5 months ago - Business Wire

FENC FINAL DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Encourages Fennec Pharmaceuticals Inc. Investors with Losses to...

New York, New York--(Newsfile Corp. - April 11, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) between...

5 months ago - Newsfile Corp

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Fennec Investors of a Lead Plaintiff Deadline of April 11,...

NEW YORK , April 11, 2022 /PRNewswire/ -- Attention Fennec Pharmaceuticals Inc. ("Fennec") (NASDAQ: FENC) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced...

5 months ago - PRNewsWire

FENC FINAL DEADLINE TOMORROW: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Fennec Pharmaceuticals Inc. Investors with Lo...

New York, New York--(Newsfile Corp. - April 10, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) between...

5 months ago - Newsfile Corp

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Fennec Pharmaceuticals ...

New York, New York--(Newsfile Corp. - April 9, 2022) - Pomerantz LLP announces that a class action lawsuit has been filed against Fennec Pharmaceuticals Inc. ("Fennec" or the "Company") (NASDAQ: FENC) a...

5 months ago - Newsfile Corp

FENC FINAL DEADLINE MONDAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Fennec Pharmaceuticals Inc. Investors with Lo...

New York, New York--(Newsfile Corp. - April 8, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) between ...

5 months ago - Newsfile Corp

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fennec Pha...

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming April 11, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors ...

5 months ago - Business Wire

FENC SHAREHOLDER ALERT: Jakubowitz Law Reminds Fennec Shareholders of a Lead Plaintiff Deadline of April 11, 2022

NEW YORK , April 8, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Fennec Pharmaceuticals Inc. (NASDAQ: FENC). To r...

5 months ago - PRNewsWire

FENC LAWSUIT ALERT: Levi & Korsinsky Notifies Fennec Pharmaceuticals Inc. Investors of a Class Action Lawsuit and Upc...

NEW YORK , April 7, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Fennec Pharmaceuticals Inc. ("Fennec" or the "Company") (NASDAQ: FENC) of a class action securities lawsuit. CLASS DE...

5 months ago - PRNewsWire

FENC MONDAY DEADLINE: ROSEN, A TOP RANKED FIRM, Encourages Fennec Pharmaceuticals Inc. Investors With Losses Over $10...

New York, New York--(Newsfile Corp. - April 6, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) between ...

5 months ago - Newsfile Corp

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Fennec Pharmaceuticals Inc. of a Class Action Lawsuit ...

NEW YORK , April 6, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Fennec Pharmaceuticals Inc.. Shareholders who purchased shares of FENC during the class period ...

5 months ago - PRNewsWire

New Strong Sell Stocks for April 5th

FENC, ALKT, and AMADY have been added to the Zacks Rank #5 (Strong Sell) List on April 5, 2022.

Other symbols: ALKT
5 months ago - Zacks Investment Research